Recruiting

Testing a new blood cancer medication against existing standard treatments

Plain-English translation of NCT07377578 on ClinicalTrials.gov ↗ · Source last updated February 2026 · Translation generated June 2026 · How we translate trials

Read our Mantle Cell Lymphoma research guide →

Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.

What is this trial?

This trial is testing a new medication called , which targets a specific protein that helps cancer cells grow. Researchers want to see if works better and is safer than other existing medications that target the same protein in patients with mantle cell lymphoma—an aggressive blood cancer—whose disease has returned or is no longer responding to previous treatment. You would receive either the new medication or one of several established standard treatments.

Mantle cell lymphoma is a serious blood cancer that often comes back even after treatment. While current medications help many patients, doctors are looking for options that might work better or have fewer side effects, which is why this new treatment is being studied.

Do you qualify?

You likely qualify if…

you have been diagnosed with mantle cell lymphoma and it has come back or stopped responding to at least one prior treatment
you have not previously received any BTK inhibitor medications (unless you had to stop one due to side effects)
you have measurable evidence of cancer on imaging or physical examination
you are in generally good health with a life expectancy of at least 12 weeks, as judged by your doctor
your blood counts, liver function, and kidney function are adequate
you are willing to use effective birth control throughout the study if you can become pregnant or father children

You likely don't qualify if…

you have an allergy to rocbrutinib or any of the other study medications
you have already tried a BTK inhibitor medication for your cancer
you have lymphoma involvement in your brain or central nervous system
you have had a heart attack or major heart problem in the past 6 months
you have an active serious infection that is not controlled, including tuberculosis

What participation looks like

If you join this trial, you will be randomly assigned to receive either or one of the other standard BTK inhibitor medications. You will take your assigned medication by mouth as directed, attend regular clinic visits for blood tests and health checks, and have imaging scans periodically to see how your cancer is responding. The study involves ongoing follow-up to track how well the treatment is working and any side effects you experience.

AI-generated summary from trial data · Jun 30, 2026 · Not medical advice

Testing a new blood cancer medication against existing standard treatments

What is this trial?

Do you qualify?

What participation looks like

Trial locations(2 sites)